HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $325 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $325.
July 26, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $325 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence the market's perception of a stock. In this case, the 'Buy' rating and $325 price target for Biogen by HC Wainwright & Co. is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100